Senesco to Present at the 53rd Annual Meeting of the American Society of Hematology on SNS01-T

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that it will deliver a poster presentation at the 53rd Annual Meeting of ASH, the American Society of Hematology. The conference will be held December 10-13th, 2011 at the San Diego Convention Center in San Diego, California. The Company will present during the Oral and Poster Abstracts Program that will begin Saturday December 10th, at 5:30 p.m. Pacific Time. The poster presentation, entitled “Pharmacodynamic, Biodistribution and Toxicology Results for SNS01-T, a Nanoparticle That Targets eIF5A for the Treatment of Multiple Myeloma”, will describe the characteristics of SNS01-T, which is the subject of an on-going clinical study at the Mayo Clinic. The poster will be presented by Catherine Taylor, Research Associate from Senesco CSO John Thompson’s research laboratory at the University of Waterloo in Ontario, Canada. Additional details about the conference can be found at: http://www.hematology.org/

About Multiple Myeloma

Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies. Malignant plasma cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal white blood cells. Median survival time from first treatment is 2½ to 5 years depending on disease stage at diagnosis. In the United States there are almost 20,000 newly diagnosed cases of multiple myeloma annually and a total of approximately 65,000 patients with the disease. Senesco was previously granted orphan drug status for SNS01-T, the Company’s lead drug candidate for treatment of multiple myeloma.

About Senesco Technologies, Inc.

Senesco Technologies is leveraging proprietary technology that regulates programmed cell death, or apoptosis. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications treating certain inflammatory and ischemic diseases. The Company has initiated a clinical study in multiple myeloma with its lead therapeutic candidate SNS01-T. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners’ products.

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance, the Company’s ability to comply with the continued listing standards of the NYSE Amex, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward looking statements to reflect subsequent events or circumstances.